person · Reporting owner

Baylor-Henry Minnie

Disclosed activity across 5 companies

Tapewire entity: 38436
SEC CIK: 0001747260

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Apyx Medical CorpAPYX · Entity 6609	Director	June 11, 2026	June 15, 2026
Lantheus Holdings, Inc.LNTH · Entity 690	Director	May 14, 2026	May 18, 2026
POLARITYTE, INC.PTE · Entity 117561	Director	January 01, 2021	January 05, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Apyx Medical Corp

Report date June 11, 2026 · Filed June 15, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Option to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.65 · Expires 2036-06-11	Direct	50,000	Reported balance After 2026-06-11 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-11 · Grant · Acquired 50,000 · Balance 50,000 F1: Reporting person was granted a stock option which shall vest ratably over a twelve (12) month period and shall become fully vested and fully exercisable on the first anniversary of the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: Reporting person was granted a stock option which shall vest ratably over a twelve (12) month period and shall become fully vested and fully exercisable on the first anniversary of the date of grant.

Lantheus Holdings, Inc.

Report date May 14, 2026 · Filed May 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	14,018	Reported balance After 2026-05-14 transaction · row 1 1 source row Row 1 · 2026-05-14 · Grant · Acquired 4,137 · Balance 14,018
Common StockSEC Table I · non-derivative	IndirectBy spouse's IRA	16	Reported balance Holding disclosure · report date 2026-05-14 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 16

POLARITYTE, INC.

Report date January 01, 2021 · Filed January 05, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	207,861	Reported balance After 2021-01-01 transaction · row 1 1 source row Row 1 · 2021-01-01 · Grant · Acquired 136,030 · Balance 207,861 F1: On January 1, 2021, the reporting person was issued under the issuer's 2017 Equity Incentive Plan 18,383 Restricted Stock Units vesting in three equal monthly installments beginning February 1, 2021, and 117,647 Restricted Stock Units vesting in 12 monthly installments beginning February 1, 2021. The Restricted Stock Units represent a total value of $92,500 in annual and quarterly compensation awarded under the issuer's non-executive director compensation plan.

Filing footnotes · ownership attribution and instrument terms

F1: On January 1, 2021, the reporting person was issued under the issuer's 2017 Equity Incentive Plan 18,383 Restricted Stock Units vesting in three equal monthly installments beginning February 1, 2021, and 117,647 Restricted Stock Units vesting in 12 monthly installments beginning February 1, 2021. The Restricted Stock Units represent a total value of $92,500 in annual and quarterly compensation awarded under the issuer's non-executive director compensation plan.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Paratek Pharmaceuticals, Inc.

Report date September 21, 2023 · Filed September 21, 2023

Section 16 reporting ended · disclosed 2023-09-21. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Ending reported balance After 2023-09-21 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2023-09-21 · Disposition to issuer · Disposed 32,800 · Balance 26,400 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 6, 2023, by and among the Issuer, Resistance Acquisition, Inc. ("Parent"), and Resistance Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into Issuer with the Issuer being the surviving corporation (the "Merger"). F2: (Continued from Footnote 1) Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock of the Issuer ("Company Common Stock") was cancelled and retired and automatically converted into the right to receive (x) $2.15, payable to the holder thereof in cash, without interest (the "Cash Consideration") but subject to reduction for any applicable withholding taxes payable in respect thereof and (y) one (1) contractual contingent value right (a "CVR Payment") that represents the right to receive $0.85 upon satisfaction of certain conditions set forth in a Contingent Value Rights Agreement, dated September 21, 2023, by and between Parent and Equiniti Trust Company, LLC. Row 2 · 2023-09-21 · Disposition to issuer · Disposed 26,400 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award covering shares of Company Common Stock that is subject to vesting conditions based solely on continued employment or service granted under an Issuer equity plan (each, a "Company RSU") and each performance stock unit award covering shares of Company Common Stock that are subject to performance-based vesting conditions granted under an Issuer equity plan (each, a "Company PSU") (the Company RSUs and the Company PSUs, collectively "Company Equity Awards") that was then outstanding was cancelled, and the holder of such cancelled Company Equity Award is entitled, in exchange therefor, to receive (without interest and less applicable tax withholdings) (i) an amount in cash equal to the product of (A) the total number of shares of Company Common Stock subject to (or deliverable under) such Company Equity Award immediately prior to the Effective Time multiplied by (B) the Cash Consideration, F4: (Continued from Footnote 3) and (ii) a CVR Payment for each share of Company Common Stock subject thereto (the "Equity Award Consideration"), provided, that any payment of the Equity Award Consideration in respect of an unvested Company Equity Award will remain subject to the same vesting conditions as were applicable to such Company Equity Award immediately prior to the Effective Time and shall only become payable to the holder of such cancelled Company Equity Award to the extent such vesting conditions are satisfied following the closing of the Merger.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.82 · Expires 2031-06-30	Direct	0	Reported balance After 2023-09-21 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-09-21 · Disposition to issuer · Disposed 12,800 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 6, 2023, by and among the Issuer, Resistance Acquisition, Inc. ("Parent"), and Resistance Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into Issuer with the Issuer being the surviving corporation (the "Merger").

F2: (Continued from Footnote 1) Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock of the Issuer ("Company Common Stock") was cancelled and retired and automatically converted into the right to receive (x) $2.15, payable to the holder thereof in cash, without interest (the "Cash Consideration") but subject to reduction for any applicable withholding taxes payable in respect thereof and (y) one (1) contractual contingent value right (a "CVR Payment") that represents the right to receive $0.85 upon satisfaction of certain conditions set forth in a Contingent Value Rights Agreement, dated September 21, 2023, by and between Parent and Equiniti Trust Company, LLC.

F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award covering shares of Company Common Stock that is subject to vesting conditions based solely on continued employment or service granted under an Issuer equity plan (each, a "Company RSU") and each performance stock unit award covering shares of Company Common Stock that are subject to performance-based vesting conditions granted under an Issuer equity plan (each, a "Company PSU") (the Company RSUs and the Company PSUs, collectively "Company Equity Awards") that was then outstanding was cancelled, and the holder of such cancelled Company Equity Award is entitled, in exchange therefor, to receive (without interest and less applicable tax withholdings) (i) an amount in cash equal to the product of (A) the total number of shares of Company Common Stock subject to (or deliverable under) such Company Equity Award immediately prior to the Effective Time multiplied by (B) the Cash Consideration,

F4: (Continued from Footnote 3) and (ii) a CVR Payment for each share of Company Common Stock subject thereto (the "Equity Award Consideration"), provided, that any payment of the Equity Award Consideration in respect of an unvested Company Equity Award will remain subject to the same vesting conditions as were applicable to such Company Equity Award immediately prior to the Effective Time and shall only become payable to the holder of such cancelled Company Equity Award to the extent such vesting conditions are satisfied following the closing of the Merger.

F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration.

scPharmaceuticals Inc.

Report date October 07, 2025 · Filed October 07, 2025

Section 16 reporting ended · disclosed 2025-10-07. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.85 · Expires 2035-06-03	Direct	Reported balance After 2025-10-07 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-10-07 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, F2: (Continued from footnote 1) without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.11 · Expires 2034-06-11	Direct	Reported balance After 2025-10-07 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-10-07 · Disposition to issuer · Disposed 19,750 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, F2: (Continued from footnote 1) without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.53 · Expires 2032-06-14	Direct	Reported balance After 2025-10-07 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-10-07 · Disposition to issuer · Disposed 16,300 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, F2: (Continued from footnote 1) without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.37 · Expires 2029-06-18	Direct	Reported balance After 2025-10-07 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-10-07 · Disposition to issuer · Disposed 6,124 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, F2: (Continued from footnote 1) without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.80 · Expires 2028-07-20	Direct	Reported balance After 2025-10-07 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2025-10-07 · Disposition to issuer · Disposed 12,248 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, F2: (Continued from footnote 1) without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option.

Filing footnotes · ownership attribution and instrument terms

F1: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash,

F2: (Continued from footnote 1) without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 11, 2026 Filed Jun 15, 2026 23:00 UTC	Apyx Medical Corp APYX · Entity 6609	GrantStock Option (Option to Buy) · Derivative	50,000	$0.00 Strike: $4.65	$0.00	Disclosure SEC source: 0001493152-26-028768 · ownership.xml · derivative · entry 1 Baylor-Henry Minnie · CIK 0001747260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2036-06-11 F1 · derivative.exercise_date: Reporting person was granted a stock option which shall vest ratably over a twelve (12) month period and shall become fully vested and fully exercisable on the first anniversary of the date of grant. Read SEC document
May 14, 2026 Filed May 18, 2026 20:35 UTC	Lantheus Holdings, Inc. LNTH · Entity 690	GrantCommon Stock	4,137	$0.00	$0.00	Disclosure SEC source: 0002064832-26-000206 · form4.xml · nonDerivative · entry 1 Baylor-Henry Minnie · CIK 0001747260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,018 Read SEC document
October 07, 2025 Filed Oct 7, 2025 16:30 UTC	scPharmaceuticals Inc. SCPH · Entity 74456	Disposition to issuerStock Option (Right to Buy) · Derivative	12,248	$0.00 Strike: $4.80	$0.00	Disclosure SEC source: 0001193125-25-233535 · ownership.xml · derivative · entry 5 Baylor-Henry Minnie · CIK 0001747260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,248 shares Expires 2028-07-20 F1 · derivative.exercise_date: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, F2 · derivative.exercise_date: (Continued from footnote 1) without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option. Read SEC document
October 07, 2025 Filed Oct 7, 2025 16:30 UTC	scPharmaceuticals Inc. SCPH · Entity 74456	Disposition to issuerStock Option (Right to Buy) · Derivative	6,124	$0.00 Strike: $3.37	$0.00	Disclosure SEC source: 0001193125-25-233535 · ownership.xml · derivative · entry 4 Baylor-Henry Minnie · CIK 0001747260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,124 shares Expires 2029-06-18 F1 · derivative.exercise_date: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, F2 · derivative.exercise_date: (Continued from footnote 1) without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option. Read SEC document
October 07, 2025 Filed Oct 7, 2025 16:30 UTC	scPharmaceuticals Inc. SCPH · Entity 74456	Disposition to issuerStock Option (Right to Buy) · Derivative	16,300	$0.00 Strike: $4.53	$0.00	Disclosure SEC source: 0001193125-25-233535 · ownership.xml · derivative · entry 3 Baylor-Henry Minnie · CIK 0001747260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,300 shares Expires 2032-06-14 F1 · derivative.exercise_date: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, F2 · derivative.exercise_date: (Continued from footnote 1) without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option. Read SEC document
October 07, 2025 Filed Oct 7, 2025 16:30 UTC	scPharmaceuticals Inc. SCPH · Entity 74456	Disposition to issuerStock Option (Right to Buy) · Derivative	19,750	$0.00 Strike: $4.11	$0.00	Disclosure SEC source: 0001193125-25-233535 · ownership.xml · derivative · entry 2 Baylor-Henry Minnie · CIK 0001747260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,750 shares Expires 2034-06-11 F1 · derivative.exercise_date: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, F2 · derivative.exercise_date: (Continued from footnote 1) without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option. Read SEC document
October 07, 2025 Filed Oct 7, 2025 16:30 UTC	scPharmaceuticals Inc. SCPH · Entity 74456	Disposition to issuerStock Option (Right to Buy) · Derivative	30,000	$0.00 Strike: $3.85	$0.00	Disclosure SEC source: 0001193125-25-233535 · ownership.xml · derivative · entry 1 Baylor-Henry Minnie · CIK 0001747260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2035-06-03 F1 · derivative.exercise_date: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, F2 · derivative.exercise_date: (Continued from footnote 1) without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option. Read SEC document
June 03, 2025 Filed Jun 5, 2025 16:59 UTC	scPharmaceuticals Inc. SCPH · Entity 74456	GrantStock Option (Right to Buy) · Derivative	30,000	$0.00 Strike: $3.85	$0.00	Disclosure SEC source: 0000950170-25-082460 · ownership.xml · derivative · entry 1 Baylor-Henry Minnie · CIK 0001747260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-06-03 F1 · derivative.exercise_date: This stock option vests in full upon the earlier of (i) June 3, 2026, or (ii) the next annual meeting of the Issuer's stockholders. Read SEC document
May 15, 2025 Filed May 19, 2025 20:31 UTC	Apyx Medical Corp APYX · Entity 6609	GrantStock Option (Option to Buy) · Derivative	59,000	$0.00 Strike: $1.48	$0.00	Disclosure SEC source: 0001641172-25-011472 · ownership.xml · derivative · entry 1 Baylor-Henry Minnie · CIK 0001747260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,000 Underlying: Common Stock · 59,000 shares Expires 2035-05-15 F1 · derivative.exercise_date: Reporting person was granted a stock option which shall vest ratably over a twelve (12) month period and shall become fully vested and fully exercisable on the first anniversary of the date of grant. Read SEC document
May 14, 2025 Filed May 16, 2025 20:38 UTC	Lantheus Holdings, Inc. LNTH · Entity 690	GrantStock Option (right to buy) · Derivative	4,543	$0.00 Strike: $78.81	$0.00	Disclosure SEC source: 0001062993-25-009689 · form4.xml · derivative · entry 3 Baylor-Henry Minnie · CIK 0001747260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,543 Underlying: Common Stock · 4,543 shares Expires 2035-05-14 Read SEC document
May 14, 2025 Filed May 16, 2025 20:38 UTC	Lantheus Holdings, Inc. LNTH · Entity 690	GrantCommon Stock	2,537	$0.00	$0.00	Disclosure SEC source: 0001062993-25-009689 · form4.xml · nonDerivative · entry 1 Baylor-Henry Minnie · CIK 0001747260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,881 Read SEC document
January 15, 2025 Filed Jan 17, 2025 21:07 UTC	Apyx Medical Corp APYX · Entity 6609	GrantStock Option (Option to Buy) · Derivative	50,000	$0.00 Strike: $1.42	$0.00	Disclosure SEC source: 0001493152-25-002761 · ownership.xml · derivative · entry 1 Baylor-Henry Minnie · CIK 0001747260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-01-15 F1 · derivative.exercise_date: Issued pursuant to the Issuer's Director Compensation Program, as amended, which provides for the issuance of a stock option to non-employee directors with an exercise price equal to the closing price of the Issuer's common stock on its principal exchange on the second trading day following the Issuer's release of its preliminary 2024 revenue. The option vests ratably over a 12-month period and becomes fully vested and exercisable on the first anniversary of the date of grant. Read SEC document
August 08, 2024 Filed Aug 12, 2024 20:50 UTC	Apyx Medical Corp APYX · Entity 6609	GrantStock Option (Option to Buy) · Derivative	17,000	$0.00 Strike: $1.02	$0.00	Disclosure SEC source: 0001493152-24-031314 · ownership.xml · derivative · entry 1 Baylor-Henry Minnie · CIK 0001747260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2034-08-08 F1 · derivative.exercise_date: Issued pursuant to the Issuer's Director Compensation Program as set forth in the Issuer's definitive proxy statement filed with the U.S. Securities and Exchange Commission on June 25, 2024, which provides for the issuance of a stock option to non-employee directors on the date of the Issuer's Annual Meeting of Stockholders. The option vests ratably over a 12-month period and becomes fully vested and exercisable on the first anniversary of the date of grant. Read SEC document
June 11, 2024 Filed Jun 13, 2024 17:00 UTC	scPharmaceuticals Inc. SCPH · Entity 74456	GrantStock Option (Right to Buy) · Derivative	19,750	$0.00 Strike: $4.11	$0.00	Disclosure SEC source: 0000950170-24-073121 · ownership.xml · derivative · entry 1 Baylor-Henry Minnie · CIK 0001747260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,750 Underlying: Common Stock · 19,750 shares Expires 2034-06-11 F1 · derivative.exercise_date: This stock option vests in full upon the earlier of (i) June 11, 2025, or (ii) the next annual meeting of the Issuer's stockholders. Read SEC document
May 09, 2024 Filed May 13, 2024 21:11 UTC	Lantheus Holdings, Inc. LNTH · Entity 690	GrantStock Option (right to buy) · Derivative	4,853	$0.00 Strike: $75.90	$0.00	Disclosure SEC source: 0000950170-24-058832 · ownership.xml · derivative · entry 3 Baylor-Henry Minnie · CIK 0001747260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,853 Underlying: Common Stock · 4,853 shares Expires 2034-05-09 Read SEC document
May 09, 2024 Filed May 13, 2024 21:11 UTC	Lantheus Holdings, Inc. LNTH · Entity 690	GrantCommon Stock	2,635	$0.00	$0.00	Disclosure SEC source: 0000950170-24-058832 · ownership.xml · nonDerivative · entry 1 Baylor-Henry Minnie · CIK 0001747260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,344 Read SEC document
September 21, 2023 Filed Sep 21, 2023 13:24 UTC	Paratek Pharmaceuticals, Inc. PRTK · Entity 109529	Disposition to issuerStock option (right to buy) · Derivative	12,800	Not disclosed Strike: $6.82	Not disclosed	Disclosure SEC source: 0000899243-23-019368 · doc4.xml · derivative · entry 3 Baylor-Henry Minnie · CIK 0001747260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,800 shares Expires 2031-06-30 F5 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. Read SEC document
September 21, 2023 Filed Sep 21, 2023 13:24 UTC	Paratek Pharmaceuticals, Inc. PRTK · Entity 109529	Disposition to issuerCommon Stock	26,400	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-23-019368 · doc4.xml · nonDerivative · entry 2 Baylor-Henry Minnie · CIK 0001747260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award covering shares of Company Common Stock that is subject to vesting conditions based solely on continued employment or service granted under an Issuer equity plan (each, a "Company RSU") and each performance stock unit award covering shares of Company Common Stock that are subject to performance-based vesting conditions granted under an Issuer equity plan (each, a "Company PSU") (the Company RSUs and the Company PSUs, collectively "Company Equity Awards") that was then outstanding was cancelled, and the holder of such cancelled Company Equity Award is entitled, in exchange therefor, to receive (without interest and less applicable tax withholdings) (i) an amount in cash equal to the product of (A) the total number of shares of Company Common Stock subject to (or deliverable under) such Company Equity Award immediately prior to the Effective Time multiplied by (B) the Cash Consideration, F4 · price: (Continued from Footnote 3) and (ii) a CVR Payment for each share of Company Common Stock subject thereto (the "Equity Award Consideration"), provided, that any payment of the Equity Award Consideration in respect of an unvested Company Equity Award will remain subject to the same vesting conditions as were applicable to such Company Equity Award immediately prior to the Effective Time and shall only become payable to the holder of such cancelled Company Equity Award to the extent such vesting conditions are satisfied following the closing of the Merger. Read SEC document
September 21, 2023 Filed Sep 21, 2023 13:24 UTC	Paratek Pharmaceuticals, Inc. PRTK · Entity 109529	Disposition to issuerCommon Stock	32,800	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-23-019368 · doc4.xml · nonDerivative · entry 1 Baylor-Henry Minnie · CIK 0001747260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,400 F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 6, 2023, by and among the Issuer, Resistance Acquisition, Inc. ("Parent"), and Resistance Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into Issuer with the Issuer being the surviving corporation (the "Merger"). F2 · price: (Continued from Footnote 1) Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock of the Issuer ("Company Common Stock") was cancelled and retired and automatically converted into the right to receive (x) $2.15, payable to the holder thereof in cash, without interest (the "Cash Consideration") but subject to reduction for any applicable withholding taxes payable in respect thereof and (y) one (1) contractual contingent value right (a "CVR Payment") that represents the right to receive $0.85 upon satisfaction of certain conditions set forth in a Contingent Value Rights Agreement, dated September 21, 2023, by and between Parent and Equiniti Trust Company, LLC. Read SEC document
August 10, 2023 Filed Aug 15, 2023 16:27 UTC	Apyx Medical Corp APYX · Entity 6609	GrantStock Option (Option to Buy) · Derivative	17,000	$0.00 Strike: $4.25	$0.00	Disclosure SEC source: 0001493152-23-028916 · ownership.xml · derivative · entry 1 Baylor-Henry Minnie · CIK 0001747260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2033-08-10 F1 · derivative.exercise_date: Reporting person was granted a stock option which shall vest ratably over a twelve (12) month period and shall become fully vested and fully exercisable on the first anniversary of the date of grant. Read SEC document
June 06, 2023 Filed Jun 8, 2023 16:15 UTC	scPharmaceuticals Inc. SCPH · Entity 74456	GrantStock Option (Right to Buy) · Derivative	17,300	$0.00 Strike: $11.71	$0.00	Disclosure SEC source: 0000899243-23-014862 · doc4.xml · derivative · entry 1 Baylor-Henry Minnie · CIK 0001747260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,300 Underlying: Common Stock · 17,300 shares Expires 2033-06-06 F1 · derivative.exercise_date: This stock option vests in full upon the earlier of (i) June 6, 2024, or (ii) the next annual meeting of the Issuer's stockholders. Read SEC document
June 02, 2023 Filed Oct 13, 2023 21:03 UTC	Lantheus Holdings, Inc. LNTH · Entity 690	SaleCommon Stock	6	$86.22	$517.35	Disclosure SEC source: 0000950170-23-053341 · ownership.xml · nonDerivative · entry 6 Baylor-Henry Minnie · CIK 0001747260 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By spouse's IRA Disclosed balance after: 16 F1 · kind: The transactions reported in this Form 4 were made by an investment advisor in an IRA for the reporting person's spouse and were not identified to the reporting person or Issuer at the time such transactions occured. Read SEC document
May 11, 2023 Filed May 15, 2023 22:41 UTC	Lantheus Holdings, Inc. LNTH · Entity 690	GrantStock Option (right to buy) · Derivative	3,798	$0.00 Strike: $99.38	$0.00	Disclosure SEC source: 0000899243-23-012998 · doc4.xml · derivative · entry 2 Baylor-Henry Minnie · CIK 0001747260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,798 Underlying: Common Stock · 3,798 shares Expires 2033-05-11 Read SEC document
May 11, 2023 Filed May 15, 2023 22:41 UTC	Lantheus Holdings, Inc. LNTH · Entity 690	GrantCommon Stock	2,012	$0.00	$0.00	Disclosure SEC source: 0000899243-23-012998 · doc4.xml · nonDerivative · entry 1 Baylor-Henry Minnie · CIK 0001747260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,709 Read SEC document
February 08, 2023 Filed Feb 9, 2023 21:04 UTC	Paratek Pharmaceuticals, Inc. PRTK · Entity 109529	GrantCommon Stock	20,000	$0.00	$0.00	Disclosure SEC source: 0000904454-23-000099 · edgar.xml · nonDerivative · entry 1 Baylor-Henry Minnie · CIK 0001747260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,200 F1 · shares: Represents restricted stock units granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the one-year anniversary of February 8, 2023, subject to the Reporting Person's continued service with the Issuer through the vesting date. Read SEC document
September 30, 2022 Filed Oct 13, 2023 21:03 UTC	Lantheus Holdings, Inc. LNTH · Entity 690	OtherCommon Stock	6	$69.77	$418.61	Disclosure SEC source: 0000950170-23-053341 · ownership.xml · nonDerivative · entry 5 Baylor-Henry Minnie · CIK 0001747260 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By spouse's IRA Disclosed balance after: 22 F1 · kind: The transactions reported in this Form 4 were made by an investment advisor in an IRA for the reporting person's spouse and were not identified to the reporting person or Issuer at the time such transactions occured. Read SEC document
September 29, 2022 Filed Oct 13, 2023 21:03 UTC	Lantheus Holdings, Inc. LNTH · Entity 690	OtherCommon Stock	6	$66.98	$401.88	Disclosure SEC source: 0000950170-23-053341 · ownership.xml · nonDerivative · entry 4 Baylor-Henry Minnie · CIK 0001747260 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By spouse's IRA Disclosed balance after: 16 F1 · kind: The transactions reported in this Form 4 were made by an investment advisor in an IRA for the reporting person's spouse and were not identified to the reporting person or Issuer at the time such transactions occured. Read SEC document
September 23, 2022 Filed Oct 13, 2023 21:03 UTC	Lantheus Holdings, Inc. LNTH · Entity 690	OtherCommon Stock	4	$75.16	$300.64	Disclosure SEC source: 0000950170-23-053341 · ownership.xml · nonDerivative · entry 3 Baylor-Henry Minnie · CIK 0001747260 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By spouse's IRA Disclosed balance after: 10 F1 · kind: The transactions reported in this Form 4 were made by an investment advisor in an IRA for the reporting person's spouse and were not identified to the reporting person or Issuer at the time such transactions occured. Read SEC document
September 19, 2022 Filed Oct 13, 2023 21:03 UTC	Lantheus Holdings, Inc. LNTH · Entity 690	OtherCommon Stock	5	$83.48	$417.42	Disclosure SEC source: 0000950170-23-053341 · ownership.xml · nonDerivative · entry 2 Baylor-Henry Minnie · CIK 0001747260 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By spouse's IRA Disclosed balance after: 6 F1 · kind: The transactions reported in this Form 4 were made by an investment advisor in an IRA for the reporting person's spouse and were not identified to the reporting person or Issuer at the time such transactions occured. Read SEC document
September 19, 2022 Filed Oct 13, 2023 21:03 UTC	Lantheus Holdings, Inc. LNTH · Entity 690	OtherCommon Stock	1	$83.79	$83.79	Disclosure SEC source: 0000950170-23-053341 · ownership.xml · nonDerivative · entry 1 Baylor-Henry Minnie · CIK 0001747260 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By spouse's IRA Disclosed balance after: 1 F1 · kind: The transactions reported in this Form 4 were made by an investment advisor in an IRA for the reporting person's spouse and were not identified to the reporting person or Issuer at the time such transactions occured. Read SEC document
August 11, 2022 Filed Aug 17, 2022 19:33 UTC	Apyx Medical Corp APYX · Entity 6609	GrantStock Option (Option to Buy) · Derivative	37,000	$0.00 Strike: $10.28	$0.00	Disclosure SEC source: 0000719135-22-000069 · wf-form4_166076477650839.xml · derivative · entry 1 Baylor-Henry Minnie · CIK 0001747260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,000 Underlying: Common Stock · 37,000 shares Expires 2032-08-11 F1 · derivative.exercise_date: Reporting person was granted a stock option which shall vest ratably over a twelve (12) month period and shall become fully vested and fully exercisable on the first anniversary of the date of grant. Read SEC document
June 14, 2022 Filed Jun 15, 2022 16:30 UTC	scPharmaceuticals Inc. SCPH · Entity 74456	GrantStock Option (Right to Buy) · Derivative	16,300	$0.00 Strike: $4.53	$0.00	Disclosure SEC source: 0000899243-22-022574 · doc4.xml · derivative · entry 1 Baylor-Henry Minnie · CIK 0001747260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,300 Underlying: Common Stock · 16,300 shares Expires 2032-06-14 F1 · derivative.exercise_date: This stock option vests in full upon the earlier of (i) June 14, 2023, or (ii) the next annual meeting of the Issuer's stockholders. Read SEC document
May 06, 2022 Filed May 10, 2022 20:35 UTC	Lantheus Holdings, Inc. LNTH · Entity 690	GrantStock Option (right to buy) · Derivative	3,616	$0.00 Strike: $64.20	$0.00	Disclosure SEC source: 0000899243-22-017440 · doc4.xml · derivative · entry 2 Baylor-Henry Minnie · CIK 0001747260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,616 Underlying: Common Stock · 3,616 shares Expires 2032-05-06 Read SEC document
May 06, 2022 Filed May 10, 2022 20:35 UTC	Lantheus Holdings, Inc. LNTH · Entity 690	GrantCommon Stock	2,180	$0.00	$0.00	Disclosure SEC source: 0000899243-22-017440 · doc4.xml · nonDerivative · entry 1 Baylor-Henry Minnie · CIK 0001747260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,697 F1 · shares: The restricted stock units cliff vest on May 6, 2023. Read SEC document
May 06, 2022 Filed May 12, 2022 21:50 UTC Amendment	Lantheus Holdings, Inc. LNTH · Entity 690	GrantStock Option (right to buy) · Derivative	4,068	$0.00 Strike: $64.20	$0.00	Disclosure SEC source: 0000899243-22-017804 · doc4a.xml · derivative · entry 1 Baylor-Henry Minnie · CIK 0001747260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,068 Underlying: Common Stock · 4,068 shares Expires 2032-05-06 F1 · shares: The Form 4 originally filed on May 10, 2022 inadvertently reported 3,616 options granted on May 6, 2022 due to an administrative error. The correct amount of options granted on May 6, 2022 is 4,068 and is being reported in this amendment. F1 · derivative.underlying_shares: The Form 4 originally filed on May 10, 2022 inadvertently reported 3,616 options granted on May 6, 2022 due to an administrative error. The correct amount of options granted on May 6, 2022 is 4,068 and is being reported in this amendment. F1 · balance_after: The Form 4 originally filed on May 10, 2022 inadvertently reported 3,616 options granted on May 6, 2022 due to an administrative error. The correct amount of options granted on May 6, 2022 is 4,068 and is being reported in this amendment. Read SEC document
March 03, 2022 Filed Mar 8, 2022 01:41 UTC	Lantheus Holdings, Inc. LNTH · Entity 690	GrantCommon Stock	517	$0.00	$0.00	Disclosure SEC source: 0000899243-22-009818 · doc4.xml · nonDerivative · entry 1 Baylor-Henry Minnie · CIK 0001747260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 517 Read SEC document
February 16, 2022 Filed Feb 18, 2022 17:09 UTC	Paratek Pharmaceuticals, Inc. PRTK · Entity 109529	GrantCommon Stock	20,000	$0.00	$0.00	Disclosure SEC source: 0000904454-22-000161 · edgar.xml · nonDerivative · entry 1 Baylor-Henry Minnie · CIK 0001747260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,200 F1 · shares: Represents restricted stock units granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the one-year anniversary of February 16, 2022, subject to the Reporting Person's continued service with the Issuer through the vesting date. Read SEC document
August 06, 2021 Filed Aug 11, 2021 19:34 UTC	Apyx Medical Corp APYX · Entity 6609	GrantStock Option (Option to Buy) · Derivative	17,000	$0.00 Strike: $9.42	$0.00	Disclosure SEC source: 0000719135-21-000058 · wf-form4_162871048053719.xml · derivative · entry 1 Baylor-Henry Minnie · CIK 0001747260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2031-08-06 F1 · derivative.exercise_date: Reporting person was granted a stock option which shall vest ratably over a twelve (12) month period and shall become fully vested and fully exercisable on the first anniversary of the date of grant. Read SEC document
June 30, 2021 Filed Jul 1, 2021 16:23 UTC	Paratek Pharmaceuticals, Inc. PRTK · Entity 109529	GrantStock Option (right to buy) · Derivative	12,800	$0.00 Strike: $6.82	$0.00	Disclosure SEC source: 0000904454-21-000570 · edgar.xml · derivative · entry 2 Baylor-Henry Minnie · CIK 0001747260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,800 Underlying: Common Stock · 12,800 shares Expires 2031-06-30 F2 · derivative.exercise_price: The exercise price is equal to the closing sales price per share of Common Stock as reported on The Nasdaq Global Market on the date of grant. F3 · derivative.exercise_date: The stock option shall vest as to 1/36 of the shares on July 31, 2021, and on the last day of each successive month thereafter until fully vested, subject to the Reporting Person's continued service with the Issuer through each vesting date. Read SEC document
June 30, 2021 Filed Jul 1, 2021 16:23 UTC	Paratek Pharmaceuticals, Inc. PRTK · Entity 109529	GrantCommon Stock	19,200	$0.00	$0.00	Disclosure SEC source: 0000904454-21-000570 · edgar.xml · nonDerivative · entry 1 Baylor-Henry Minnie · CIK 0001747260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,200 F1 · shares: Represents restricted stock units granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan, pursuant to the Paratek Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, effective January 1, 2021. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest as to 1/3 of the shares subject to the restricted stock units on June 30, 2022, and on the same calendar date of each successive year thereafter until fully vested, subject to the Reporting Person's continued service with the Issuer through each vesting date. Read SEC document
June 08, 2021 Filed Jun 10, 2021 16:50 UTC	scPharmaceuticals Inc. SCPH · Entity 74456	GrantStock Option (Right to Buy) · Derivative	16,300	$0.00 Strike: $5.70	$0.00	Disclosure SEC source: 0000899243-21-022981 · doc4.xml · derivative · entry 1 Baylor-Henry Minnie · CIK 0001747260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,300 Underlying: Common Stock · 16,300 shares Expires 2031-06-08 F1 · derivative.exercise_date: This stock option vests in full upon the earlier of (i) June 8, 2022, and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document
January 01, 2021 Filed Jan 5, 2021 16:10 UTC	POLARITYTE, INC. PTE · Entity 117561	GrantCommon Stock	136,030	$0.68	$92,500.40	Disclosure SEC source: 0001493152-21-000210 · ownership.xml · nonDerivative · entry 1 Baylor-Henry Minnie · CIK 0001747260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,861 F1 · shares: On January 1, 2021, the reporting person was issued under the issuer's 2017 Equity Incentive Plan 18,383 Restricted Stock Units vesting in three equal monthly installments beginning February 1, 2021, and 117,647 Restricted Stock Units vesting in 12 monthly installments beginning February 1, 2021. The Restricted Stock Units represent a total value of $92,500 in annual and quarterly compensation awarded under the issuer's non-executive director compensation plan. Read SEC document
December 10, 2020 Filed Dec 10, 2020 16:15 UTC	POLARITYTE, INC. PTE · Entity 117561	Exercise / conversionRestricted Stock Units · Derivative	2,992	$0.00	$0.00	Disclosure SEC source: 0001493152-20-023267 · ownership.xml · derivative · entry 2 Baylor-Henry Minnie · CIK 0001747260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,991 Underlying: Common Stock · 2,992 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. On December 10, 2018, the reporting person was granted 8,975 restricted stock units that vest at the rate of 2,992 shares on December 10, 2019 and 2020, and 2,991 shares on December 10, 2021. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. On December 10, 2018, the reporting person was granted 8,975 restricted stock units that vest at the rate of 2,992 shares on December 10, 2019 and 2020, and 2,991 shares on December 10, 2021. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. On December 10, 2018, the reporting person was granted 8,975 restricted stock units that vest at the rate of 2,992 shares on December 10, 2019 and 2020, and 2,991 shares on December 10, 2021. Read SEC document
December 10, 2020 Filed Dec 10, 2020 16:15 UTC	POLARITYTE, INC. PTE · Entity 117561	Exercise / conversionCommon Stock	2,992	Not disclosed	Not disclosed	Disclosure SEC source: 0001493152-20-023267 · ownership.xml · nonDerivative · entry 1 Baylor-Henry Minnie · CIK 0001747260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,831 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. On December 10, 2018, the reporting person was granted 8,975 restricted stock units that vest at the rate of 2,992 shares on December 10, 2019 and 2020, and 2,991 shares on December 10, 2021. Read SEC document
October 01, 2020 Filed Oct 5, 2020 16:05 UTC	POLARITYTE, INC. PTE · Entity 117561	GrantCommon Stock	12,135	$1.03	$12,499.05	Disclosure SEC source: 0001493152-20-018912 · ownership.xml · nonDerivative · entry 1 Baylor-Henry Minnie · CIK 0001747260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,839 F1 · shares: On October 1, 2020, the reporting person was issued 12,135 Restricted Stock Units vesting in three equal monthly installments beginning November 1, 2020. The Restricted Stock Units were issued in lieu of quarterly director fees in the amount of $12,500 under the 2019 Equity Incentive Plan. Read SEC document
August 06, 2020 Filed Aug 10, 2020 21:22 UTC	Apyx Medical Corp APYX · Entity 6609	GrantStock Option (Option to Buy) · Derivative	17,000	$4.98 Strike: $4.98	$84,660.00	Disclosure SEC source: 0000719135-20-000061 · wf-form4_159709450745295.xml · derivative · entry 1 Baylor-Henry Minnie · CIK 0001747260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2030-08-06 F1 · derivative.exercise_date: Reporting person was granted a stock option which shall vest ratably over a twelve (12) month period and shall become fully vested and fully exercisable on the first anniversary of the date of grant. Read SEC document
June 09, 2020 Filed Jun 11, 2020 16:16 UTC	scPharmaceuticals Inc. SCPH · Entity 74456	GrantStock Option (Right to Buy) · Derivative	6,124	$0.00 Strike: $7.96	$0.00	Disclosure SEC source: 0000899243-20-016165 · doc4.xml · derivative · entry 1 Baylor-Henry Minnie · CIK 0001747260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,124 Underlying: Common Stock · 6,124 shares Expires 2030-06-09 F1 · derivative.exercise_date: This stock option vests in full upon the earlier of (i) June 9, 2021, and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document
April 01, 2020 Filed Apr 3, 2020 08:00 UTC	POLARITYTE, INC. PTE · Entity 117561	GrantCommon Stock	11,574	Not disclosed	Not disclosed	Disclosure SEC source: 0001493152-20-005754 · ownership.xml · nonDerivative · entry 1 Baylor-Henry Minnie · CIK 0001747260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,704 F1 · price: The shares were issued as restricted share units pursuant to the 2019 Equity Incentive Plan for a quarterly director fee in the amount of $12,500, or $1.08 per share, and vest in three equal monthly installments beginning May 1, 2020. Read SEC document
January 02, 2020 Filed Jan 6, 2020 16:05 UTC	POLARITYTE, INC. PTE · Entity 117561	GrantCommon Stock	38,269	Not disclosed	Not disclosed	Disclosure SEC source: 0001493152-20-000216 · ownership.xml · nonDerivative · entry 1 Baylor-Henry Minnie · CIK 0001747260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,130 F1 · price: The shares were issued as restricted share units pursuant to the 2019 Equity Incentive Plan for annual director fees totaling $99,500 or $2.60 per share. The shares vest in 12 equal monthly installments beginning February 1, 2020. Read SEC document
December 10, 2019 Filed Dec 10, 2019 16:30 UTC	POLARITYTE, INC. PTE · Entity 117561	Exercise / conversionRestricted Stock Units · Derivative	2,992	$0.00	$0.00	Disclosure SEC source: 0001493152-19-018980 · ownership.xml · derivative · entry 2 Baylor-Henry Minnie · CIK 0001747260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,983 Underlying: Common Stock · 2,992 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. On December 10, 2018, the reporting person was granted 8,975 restricted stock units that vest at the rate of 2,992 shares on December 10, 2019 and 2020, and 2,991 shares on December 10, 2021. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. On December 10, 2018, the reporting person was granted 8,975 restricted stock units that vest at the rate of 2,992 shares on December 10, 2019 and 2020, and 2,991 shares on December 10, 2021. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. On December 10, 2018, the reporting person was granted 8,975 restricted stock units that vest at the rate of 2,992 shares on December 10, 2019 and 2020, and 2,991 shares on December 10, 2021. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.